Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin in Osteoarticular Infections Associated With Hip and Knee Replacements
NCT05046860Active, not recruiting
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Mar 2022
- Primary completion
- Aug 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dalbavancin in Osteoarticular infection (OAI), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Therapeutic Success at 12 months. Started Mar 2022; status: active, not recruiting.
02
Drugs
dalbavancin
03
Conditions
Osteoarticular infection (OAI)
Beyond the preview
Go deeper on NCT05046860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05046860.